Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest Cadence Pharmaceuticals Inc. Stories

2013-03-12 08:28:54

SAN DIEGO, March 12, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), announced today that the Department of Veterans Affairs has made OFIRMEV(®) (acetaminophen) injection available on the VA National Formulary (VANF). The VANF is a list of products (drugs and supplies) generally covered under VA pharmacy benefits. VANF products must be available for prescription at all VA facilities. The purpose of the VANF management process is to provide high quality, best value...

2013-03-07 08:28:40

-- 2012 Net Product Revenue Exceeds $50 Million -- SAN DIEGO, March 7, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the fourth quarter and full year ended December 31, 2012. For the fourth quarter of 2012, Cadence reported net product revenue from sales of...

2013-03-06 20:22:11

SAN DIEGO, March 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags. Previously, Cadence announced the extension of...

2013-02-28 16:29:21

SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2012 financial results on Thursday, March 7, 2013. Cadence management will host a conference call and live webcast to discuss the financial results on...

2013-02-26 16:27:13

SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Tuesday, March 5, 2013 at 11:20am Eastern Time (8:20am Pacific Time) during the Cowen & Company 33(rd) Annual Health...

2013-02-06 20:21:10

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, February 13, 2013 at 3:30pm Eastern Time (12:30pm Pacific Time) during the Leerink Swann Global Healthcare Conference at...

2013-01-23 08:28:21

SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a preliminary (unaudited) estimate of net product revenue from sales of OFIRMEV(®) (acetaminophen) injection for the three-months ended December 31, 2012, of approximately $17.1 million. "We ended 2012 on a high note, with...

2012-12-12 08:27:23

SAN DIEGO, Calif., Dec. 12, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that it has entered into an agreement to terminate its exclusive option to acquire privately-held Incline Therapeutics, Inc., or Incline. Under the waiver, consent and option termination agreement signed by Cadence and...

2012-11-28 16:25:37

SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company will host an Analyst and Investor Day for financial analysts on Thursday, December 6, 2012, from 9:00 am to 12:00 pm EST in New York, NY. Members of the Cadence senior management team will provide an update on the...

2012-11-28 08:28:58

SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has entered into settlement and license agreements with Perrigo Company (Nasdaq: PRGO; TASE), and its subsidiary, Paddock Laboratories, LLC, to resolve pending patent litigation involving OFIRMEV® (acetaminophen) injection. The settlement agreement includes a stipulation by the parties requesting dismissal with prejudice of the lawsuit filed by Cadence in the U.S. District Court...